Grown Rogue International (GRUSF) Net Income towards Common Stockholders (2013 - 2026)
Grown Rogue International (GRUSF) recorded quarterly Net Income towards Common Stockholders of -$2.7 million in Q1 2026, up 100.0% quarter-over-quarter from -$5017.9 billion in Q4 2025, and down 551.29% on a YoY basis from $598782.0 in Q1 2025.
Grown Rogue International (GRUSF) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Grown Rogue International's Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at -$2.7 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 551.29% year-over-year to -$2.7 million; the TTM figure through Mar 2026 stood at -$2319.6 billion (down 190.48% YoY), while the FY2025 annual figure was -$452962.0, up 97.17% from the prior year.
- Net Income towards Common Stockholders was -$2.7 million for Q1 2026 at Grown Rogue International, up from -$5017.9 billion in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $2698.3 billion in Q3 2025 to a low of -$5017.9 billion in Q4 2025.
- Historically, Net Income towards Common Stockholders has averaged -$222.7 billion across 5 years, with a median of -$4989.0 in 2022.
- The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders surged 437.92% in 2025, then slumped 551.29% in 2026.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$422824.0 in 2022, then jumped by 252.03% to $642820.0 in 2023, then slumped by 124220877.2% to -$798.5 billion in 2024, then slumped by 528.4% to -$5017.9 billion in 2025, then jumped by 100.0% to -$2.7 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$2.7 million (Q1 2026), -$5017.9 billion (Q4 2025), and $2698.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Grown Rogue International | - | - | 3.96 Mn | -2.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.70 Mn |
| Dec 31, 2025 | -5,017.87 Bn |
| Sep 30, 2025 | 2,698.31 Bn |
| Jun 30, 2025 | 1.32 Mn |
| Mar 31, 2025 | 598,782.00 |
| Sep 30, 2024 | -798.52 Bn |
| Jun 30, 2024 | -5.62 Mn |
| Mar 31, 2024 | -4.20 Mn |
| Dec 31, 2023 | 642,820.00 |
| Oct 31, 2023 | -1.47 Mn |
| Jul 31, 2023 | 640,713.00 |
| Apr 30, 2023 | 412,846.00 |
| Jan 31, 2023 | 931,945.00 |
| Jan 31, 2022 | -422,824.00 |
| Jul 31, 2021 | -54,533.00 |
| Apr 30, 2021 | -1.43 Mn |
| Jan 31, 2021 | -1.08 Mn |
| Oct 31, 2020 | 26,352.00 |
| Jul 31, 2020 | -798,200.00 |
| Apr 30, 2020 | -1.28 Mn |